Nanjing Leads Biolabs Co., Ltd. (HKG:9887)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
69.95
+3.90 (5.90%)
Sep 30, 2025, 4:08 PM HKT
5.90%
Market Cap13.91B
Revenue (ttm)n/a
Net Income (ttm)-314.72M
Shares Out198.89M
EPS (ttm)-2.04
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,253,027
Average Volume792,762
Open66.05
Previous Close66.05
Day's Range65.00 - 70.00
52-Week Range57.45 - 83.60
Betan/a
RSI56.45
Earnings DateNov 28, 2025

About Nanjing Leads Biolabs

Nanjing Leads Biolabs Co., Ltd., a clinical-stage biotechnology company, engages in the research, development, and commercialisation of novel antibody drugs worldwide. It develops therapies in oncology, autoimmune, and other severe diseases. The company’s lead product LBL-024, a PD-L1/4-1BB bispecific antibody for extra-pulmonary neuroendocrine carcinoma, as well as LBL-034, LBL-033, and LBL-007. In addition, it develops LeadsBody platform, a portfolio of CD3 T-cell engagers that demonstrate anti-tumor efficacy and safety in preclinical/clinica... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2012
Country China
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 9887
Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements

News

There is no news available yet.